New hepatitis C virus (HCV) drugs and the hope for a cure: Concepts in anti-HCV drug development

Seminars in Liver Disease

Volumn 34, Issue 1, 2014, Pages 22-29

  Pawlotsky, Jean Michel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

direct acting antivirals; hepatitis C virus; host targeted agents; simeprevir; sofosbuvir

Indexed keywords

ABT 072; ABT 450; ACH 2928; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; ATAZANAVIR; BECLABUVIR; BMS 824393; BOCEPREVIR; DACLATASVIR; DANOPREVIR; DASABUVIR; DELDEPREVIR; DELEOBUVIR; FALDAPREVIR; FILIBUVIR; GS; GSK 2336805; IDENIX; IDX 320; LEDIPASVIR; LOMIBUVIR; MERICITABINE; MIRAVIRSEN; MK 5172; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NS 3 4A; OMBITASVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; SOVAPREVIR; TEGOBUVIR; TELAPREVIR; TMC 647055; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VEDROPREVIR; VX 135;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; GENETIC RISK; HEALTH CARE ACCESS; HEALTH CARE NEED; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK MANAGEMENT; TREATMENT DURATION; VIRAL CLEARANCE; ANIMAL; DRUG COMBINATION; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C, CHRONIC; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84899627261     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1371007     Document Type: Article

References (42)

1. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science: 1989; 244 4902 359 362 (Pubitemid 19117877)
2. Hoofnagle J. H., Mullen K. D., Jones D. B., et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med: 1986; 315 25 1575 1578 (Pubitemid 17055392)
3. Reichard O., Andersson J., Schvarcz R., Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet: 1991; 337 8749 1058 1061
4. Pawlotsky J. M., Dahari H., Neumann A. U., et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology: 2004; 126 3 703 714 (Pubitemid 38298318)
5. Fried M. W., Shiffman M. L., Reddy K. R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med: 2002; 347 13 975 982
6. Manns M. P., McHutchison J. G., Gordon S. C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet: 2001; 358 9286 958 965 (Pubitemid 32913521)
7. Pawlotsky J. M. Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol: 2013; 369 321 342
8. Lanford R. E., Guerra B., Lee H., et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol: 2003; 77 2 1092 1104 (Pubitemid 36055531)
9. Ge D., Fellay J., Thompson A. J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature: 2009; 461 7262 399 401
10. Neumann A. U., Lam N. P., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science: 1998; 282 5386 103 107 (Pubitemid 28471138)
11. Dahari H., Guedj J., Perelson A. S., Layden T. J. Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr Hepat Rep: 2011; 10 3 214 227
12. Rupp D., Bartenshlager R. Targets for antiviral therapy of hepatitis C. Semin Liver Dis: 2014; 34 9 21
13. Flisiak R., Horban A., Gallay P., et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology: 2008; 47 3 817 826 (Pubitemid 351449673)
14. Janssen H. L., Reesink H. W., Lawitz E. J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med: 2013; 368 18 1685 1694
15. Delang L., Vliegen I., Leyssen P., Neyts J. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. J Hepatol: 2012; 56 1 41 48
16. Pawlotsky J. M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology: 2011; 53 5 1742 1751
17. Chu T. W., Kulkarni R., Gane E. J., et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology: 2012; 142 4 790 795
18. Zeuzem S., Soriano V., Asselah T., et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med: 2013; 369 7 630 639
19. Jacobson I. M., Gordon S. C., Kowdley K. V., et al. POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med: 2013; 368 20 1867 1877
20. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med: 2013; 368 20 1878 1887
21. Zeuzem S., Dusheiko G. M., Salupere R., et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology: 2013; 58 01 733A
22. Guedj J., Perelson A. S. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology: 2011; 53 6 1801 1808
23. Thomas E., Ghany M. G., Liang T. J. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother: 2012; 23 1 1 12
24. Back D., Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis: 2013; 45 05 S343 S348
25. Bacon B. R., Gordon S. C., Lawitz E., et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med: 2011; 364 13 1207 1217
26. Hézode C., Fontaine H., Dorival C., et al. CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol: 2013; 59 3 434 441
27. Jacobson I. M., McHutchison J. G., Dusheiko G., et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med: 2011; 364 25 2405 2416
28. McHutchison J. G., Manns M. P., Muir A. J., et al. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med: 2010; 362 14 1292 1303
29. Poordad F., McCone J. Jr, Bacon B. R., et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med: 2011; 364 13 1195 1206
30. Jacobson I., Dore G. J., Foster G. R., et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a Phase III trial. J Hepatol: 2013; 58 01 S574
31. Manns M., Marcellin P., Poordad F. PF., et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a Phase III trial. J Hepatol: 2013; 58 01 S568
32. Poordad F., Manns M. P., Marcellin P., et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a Phase III trial. Gastroenterology: 2013; 144 S151 S151
33. Lam A. M., Espiritu C., Bansal S., et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother: 2012; 56 6 3359 3368
34. Haudecoeur R., Peuchmaur M., Ahmed-Belkacem A., Pawlotsky J. M., Boumendjel A. Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research. Med Res Rev: 2013; 33 5 934 984
35. Guedj J., Dahari H., Rong L., et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A: 2013; 110 10 3991 3996
36. McGivern D. R., Masaki T., Ping L. F., et al. Kinetic analyses of antiviral suppression by NS5A inhibitors reveal early and potent inhibition of viral assembly and release of infectious virus. Hepatology: 2013; 58 01 246A
37. Pawlotsky J. M. NS5A inhibitors in the treatment of hepatitis C. J Hepatol: 2013; 59 2 375 382
38. Pawlotsky J. M., Sarin S. K., Foster G. R., et al. Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study. Hepatology: 2012; 56 309A 310A
39. Jacobson I. M., Ghalib R. H., Rodriguez-Torres M., et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study. Hepatology: 2013; 58 01 1379A
40. Abbvie. Abbvie releases first of six phase III results from investigational all-oral, interferon-free, 12-week regimen, showing 96 percent SVR12 in genotype 1 hepatitis C patients new to therapy. Available at: http://abbvie.mediaroom.com/2013-11-18-AbbVie-Releases-First-of-Six-Phase-III- Results-from-Investigational-All-Oral-Interferon-Free-12-week-Regimen-Showing- 96-Percent-SVR12-in-Genotype-1-Hepatitis-C-Patients-New-to-Therapy. Accessed February 1, 2014
41. Abbvie. Abbvie demonstrates 96 percent SVR-12 in its phase III study of treatment experienced patients with genotype 1 hepatitis C. Available at: http://abbvie.mediaroom.com/2013-12-10-AbbVie-Demonstrates-96-percent-SVR-12-in- its-Phase-III-Study-of-Treatment-Experienced-Patients-with-Genotype-1-Hepatitis- C
42. Gilead. Gilead announces SVR12 rates from three phase 3 studies evaluating a once daily fixed dose-combination-of-sofosbuvir-and-ledipasvir-for- genotype-1-hepatitis C patients. Available at: http://www.gilead.com/news/press- releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies- evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for- genotype-1-hepatitis-c-patients?mode=print. Accessed February 1, 2014